GSK's long-acting HIV med Cabenuva equals Gilead's daily Biktarvy
Leon Neal


GlaxoSmithKline's (NYSE:GSK) Viiv Healthcare division said a phase 3 study of its every two months dosed HIV injectable therapy Cabenuva (cabotegravir/rilpivirine) was as effective as Gilead Sciences (NASDAQ:GILD) daily pill Biktarvy (bictegravir/emtricitabine/tenofovir).
Results from the SOLAR study showed that patients who had their HIV suppressed while on Biktarvy who were then switched to Cabenuva still had suppression a year later.

ViiV noted that 90% of the patients who switched to Cabenuva preferred the long-acting injection over a daily pill.
"The future of HIV treatment and prevention is long-acting," Kimberly Smith, head of R&D at ViiV, told Reuters.
Read why Seeking Alpha contributor Clinically Sound Investor recently rated GSK (GSK) a buy.